
|Articles|February 24, 2010
VEGF Trap-Eye shows positive results in a phase 2 study in patients with diabetic macular oedema
VEGF Trap-Eye, the fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related Placental Growth Factor (PIGF), has shown positive results in a Phase 2 study in patients with diabetic macular oedema (DME.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
The accessibility barriers still hindering ophthalmology
2
FLORetina Congress celebrates 10 years with joint World Retinopathy of Prematurity meeting
3
FLORetina 2025: Industry advances front and center at FLORetina Congress
4
Revisiting an overlooked solution for high myopia
5
















































